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INTRODUCTION
Recent studies have detected oncogenic HPV in 25.9% of head and neck cancers (mostly HPV16) and this prevalence increases to more than 50% for cancers of the oropharynx (tonsil, base of tongue, etc) with a growing world wide incidence (1) .
Although these tumors frequently have aggressive histopathological features (2) , the presence of HPV DNA is a favorable prognostic factor with regard to recurrence and survival (3) (4) (5) .
The mechanisms underlying the more favorable outcome of HPV-associated head and neck cancer have not been clearly elucidated.
These tumors are more responsive to chemotherapy and radiotherapy, but even patients with HPV-positive oropharyngeal cancers treated by surgery alone, have a better prognosis than those with HPV-negative tumors after adjustment for tumor stage (6, 7) .
HPV E6-E7 expressing tumors grew slower in immunocompetent mice but not in nude mice, than HPV negative tumors suggesting a role of adaptive immunity and not simply an intrinsic biological property of HPV positive tumor cells to explain this difference (8) .
In human, T cells directed against HPV derived proteins (E2, E6, E7) have been described in the blood and in the tumor of patients with head and neck cancers (9) (10) (11) (12) . However, the capacity of tumor-infiltrating lymphocytes (TILs) to act as effector cells may be affected by the tumor microenvironment. Immunosuppressive cells or molecules (13, 14) or chronic inflammation in head and neck cancer predispose to a tumor promoting microenvironment (15, 16) . Analysis of differences in the type of immunity within the tumor microenvironment of HPV-associated head and neck cancer compared to HPV-negative tumors may therefore provide new clues to explain the more favorable clinical behavior of this type of cancer. In the present study, we addressed the clinical significance of regulatory Foxp3 All these data therefore support a comprehensive analysis of PD-1-PD-L1 expression in head and neck cancers associated with chronic viral infection.
As expected, HPV-associated head and neck cancers were found to be associated with a good 
Material and Methods

Patients
Sixty four newly diagnosed untreated patients with primary histologically proven head and neck squamous cell carcinoma (HNSCC) were included in this study. Patient characteristics PD-1-expressing T cells in HPV-associated oral cancers.
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are presented in Table S1 . Patients were divided in two groups depending on the presence or absence of oncogenic HPV.
These two groups were matched for various parameters (gender, primary tumor site, tumor staging, lymph node involvement, presence of metastasis, treatment modalities) (Table S1 ).
Mice
Six to eight-week-old female C57BL/6 (H- PD-1-expressing T cells in HPV-associated oral cancers.
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Peptide, vaccine, antibodies
Pool of 15 mer peptides spanning the entire HPV16 E7 protein were designed with a 4 mer overlap between each peptide. They were obtained from PolyPeptide Laboratories (Strasbourg, France), reconstituted in PBS and stored at -20°C.
The STxB-E7 [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] vaccine was produced by chemical coupling between the Nbromoacetylated E7 [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] peptide and the sulfhydryl group of STxB-Cys recombinant protein, as previously described (23) . After purification, endotoxin concentrations determined by the Limulus assay test (Lonza. Verviers. Belgium) were < 0.5 EU/mg.
The invariant NKT cell ligand Į-GalCer (KRN7000) was purchased from Funakoshi (Tokyo, Japan).
CT-011 is a humanized monoclonal anti-PD-1 antibody manufactured by CureTech LTD (Israel). This antibody has already been validated in ex vivo functional assays in humans (24) .
Anti-mouse PDL-1 and isotype control antibodies were purchased from BioXcell (West Lebanon, U.S.A). Mice received intraperitoneal injections of 200 μg mAb/mouse as previously described (25) .
For immunofluorescence analysis, an anti-PD-1 mAb generated by D Olive's group was selected and used (see Table S2 ) as previously described (26) .
HPV detection
The presence of HPV in head and neck cancer biopsies was detected using the INNO-LIPA genotyping Extra assay (Innogenetics, Ghent, Belgium).
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Immunofluorescence staining and flow cytometry analysis
Immunofluorescence staining and flow cytometry analysis were performed as previously described (16) and detailed in supplementary data. The antibodies used for the various immunofluorescence stainings are described in Supplementary Table S2 .
Immunization of mice and in vivo tumor protection C57BL/6 mice were immunized via the intraperitoneal route at day 0 and day 14 with the STxB-E7 vaccine (20 μg) combined with 1 μg of αGalCer during the first immunization.
In a therapeutic setting experiment, 10 5 TC1 tumor cells were injected subcutaneously (s.c.) in the right flank of B6 mice. They were then vaccinated or not at day 9 and day 18 after tumor graft in combination with anti-PD-L1 or isotype control antibodies. Mice were monitored every 48-72h for tumor growth.
Statistical analysis
Survival variables were estimated using the Kaplan-Meier method and compared by the logrank test for categorical variables and the Cox model and associated Wald x2 statistic for quantitative variables.
Overall survival was defined as the time from initial diagnosis until death or until last followup (right censored data).
Locoregional control was calculated from the end of treatment and defined as the absence or either persistent or recurrent disease at the primary site or in the cervical lymph nodes.
Patients with persistent disease at the end of treatment were considered to have experienced failure at time zero. Patients with no signs of relapse were censored at the time of last-follow up or death. The median follow-up for the overall population was 26 months.
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The Mann-Whitney U-test was used to assess whether two samples of observations were derived from the same distribution. The Chi-square test with Yates correction was used to analyze the relationship between tumor cell infiltration and the tumor HPV status.
RESULTS
HPV-associated head and neck cancer has a good prognosis
In a retrospective study, we divided 64 head and neck cancer patients into two groups differing according to presence or absence of oncogenic HPV (30 HPV16, 1 HPV18 and 1 HPV33, 32 HPV negative) in their tumors. These two groups were balanced for gender, primary tumor sites, tumor (T) staging, lymph node involvement and treatment modalities (Table S1 ). Based on Kaplan-Meier estimates, the overall survival for patients with HPVpositive cancer was significantly better (median survival not reached) than for patients with HPV-negative cancer (median survival : 16 months) (p = 0.001)(log rank test) (Fig 1) . Patients with HPV-positive tumors also had a significantly better disease-free survival (p = 0.003)(log rank test) than patients with HPV-negative cancer (Fig 1) . PD-1-expressing T cells in HPV-associated oral cancers. Thirty Three (51.5%) of the 64 head and neck tumors expressed significant levels of PD-L1
Intratumoral
(score ++/+++) with homogeneous staining (Table 1 and Fig S2) , but no correlation was observed between PD-L1 expression and HPV status of these head and neck cancer patients (Table 1 (Fig 3B) .
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In contrast, the levels of infiltration by CD8 (Fig 3A) . However, as previously reported by us and other authors (17, 27) , the number of Foxp3 regulatory T cells was correlated with better 18-month overall survival in the whole population of head and neck cancer patients (p = 0.0033) (Fig S3) .
PDL-1 expression was not correlated with overall survival or disease free survival in either the whole head and neck cancer cohort or in HPV-positive patients (Fig S2) . (Fig S4) .
PD-1 is a hallmark of both activated and exhausted T cells (28) . We found that PD-1 positive T cells, either CD4 or CD8 + T cells, expressed higher levels of HLA-DR and CD38 than PD-1 negative T cells (Fig 4 B and C (Fig 4D) .
We also showed that PD-1-positive cells did not express the Foxp3 marker of regulatory T cells, despite the fact that, in some cases, PD-1-positive cells and Foxp3 regulatory T cells were in close contact (Fig S5B) .
To assess whether the functionality of these T cells could be enhanced, fresh TIL were co- (Fig 5) . An isotype control antibody had no effect on enhanced IFNγ production (Fig 5) .
In one HPV positive patient, E7 peptides slightly increased the frequency of CT-011 induced IFNγ secretion (Fig 5) .
Vaccination increases PD-1 and PD-1 blockade synergizes with the vaccine anti-tumor effect.
To explain this paradoxical good prognostic value of PD-1 + T cell infiltration in HPVassociated head and neck cancer, we modelized this phenomenon in a preclinical model. When mice were grafted with an epithelial tumor cell line (TC1) expressing the E7 protein derived from HPV, tumors were poorly infiltrated by CD8 + T cells which expressed low levels of PD-1 (6%) (Fig 6 A) .
When mice were vaccinated with a non replicative delivery vector targeting dendritic cells, the B subunit of Shiga toxin, coupled to E7, 44% of CD8 + T cells expressed PD-1 (Fig 6A and   B ). In addition, 89% of specific anti-E7 49-57 CD8 + T cells, induced by the vaccine, also expressed PD-1 (Fig 6 A and B) . The vaccine therefore appeared to elicit PD-1 expression in PD-1-expressing T cells in HPV-associated oral cancers.
12 both total and E7 49-57 specific CD8 + T cells. The vaccine alone had a partial inhibitory effect on the growth of established TC1 tumors (Fig 6D) . This effect was significantly enhanced by the addition of anti-PD-L1 (Fig 6D) . In contrast, the anti-PD-L1 antibody alone had no effect on tumor growth (Fig 6D) , which may be explained by the low (6%) PD-1 expression in infiltrating T cells in the absence of vaccination (Fig 6A) . Similar results were obtained, when overall survival or the percentage of tumor-free mice were selected as endpoints (Fig S6) 
Discussion
This study shows that HPV-positive head and neck tumors were heavily infiltrated by PD- PCR in colorectal carcinoma was also associated with a good prognosis (38) . It is therefore noteworthy that the three tumors (lymphoma, colorectal cancer and head and neck cancer), in which PD-1 expression was significantly associated with a favorable outcome (37, 38) , were also those with an unexpected clinical benefit of Treg infiltration (17, 39, 40) . The present study, conducted in an independent series of patients, confirms our previous findings that high levels of Treg in head and neck cancer patients were also positively correlated with a better prognosis (17) . These results concerning the good prognostic value of intratumor regulatory T cells in head and neck cancer have subsequently been reproduced by various groups (27, 41) .
In addition, the frequency of regulatory Foxp3 Indeed, we showed that PD-1-positive T cells expressed higher levels of the HLA-DR and CD38 activation markers, than PD-1-negative T cells (Fig 4) . 
